Regenicin Conducts an Evaluation of its Proprietary Collagen-Based Scaffold

Regenicin Conducts an Evaluation of its Proprietary Collagen-Based Scaffold
for Use in New Autologous Cultured Skin Substitute

 
(Little Falls, NJ) – October 5, 2016 - Regenicin, Inc. (OTC Bulletin Board: RGIN), a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, today announced that New Jersey Institute of Technology (NJIT) has evaluated Regenicin’s proprietary closed-herd, collagen-based scaffold used to grow Regenicin’s cultured skin substitute, NovaDerm®. The NJIT researchers observed that skin cells grew on bovine closed-herd collagen scaffolds in laboratory testing.
 
NovaDerm, which recently received its orphan-drug designation from the U.S. Food and Drug Administration (FDA), is a regenerative cell therapy that has the potential to re-grow a patient’s own skin in a laboratory by harvesting a small, stamp-size skin biopsy.
 
In the course of their evaluation, NJIT researchers observed that with some modifications to commercially available media, NovaDerm appeared to speed up cell growth of harvested fibroblast and keratinocytes. Strong cell viability was observed twenty eight days after initial seeding on Regenicin’s proprietary bovine closed-herd collagen scaffold. As a result, Regenicin’s product development team will be investigating whether this could lead to a longer shelf life than previously expected.
 
In addition, materials from a bovine closed-herd have an enormous advantage in that the animals within the entire herd are not exposed to potential carriers of diseases or parasites from cows or other animal species. Using collagen that comes from a bovine closed-herd is a significant breakthrough in safety, as closed herd quality systems are designed to minimize exposure to pathogens which could be transferred to humans when using animal components for healthcare. Regenicin will only use bovine closed herd collagen to produce NovaDerm®
 
“We are extremely pleased with the outcome of the study,” says Randall McCoy, CEO of Regenicin. “We have met another key milestone for the company and will continue to focus our energies on preparing NovaDerm for clinical trials.”

return to 2016 Press and News Releases
return to Home Page

About Regenicin
Regenicin, Inc. (OTC Bulletin Board: RGIN), is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New Jersey. For more information on Regenicin, Inc., as well as its technologies and products, please visit the company website at www.regenicin.com.

About NJIT
One of the nation’s leading public technological universities, NJIT is a top-tier research university that prepares students to become leaders in the technology-dependent economy of the 21st century. NJIT’s multidisciplinary curriculum and computing-intensive approach to education provide technological proficiency, business acumen and leadership skills. With an enrollment of 11,300 graduate and undergraduate students, NJIT offers small-campus intimacy with the resources of a major public research university. NJIT is a global leader in such fields as solar research, nanotechnology, resilient design, tissue engineering and cybersecurity, in addition to others. NJIT ranks fifth among U.S. polytechnic universities in research expenditures, topping $120 million, and is among the top 1 percent of public colleges and universities in return on educational investment, according to PayScale.com. NJIT has a $1.74 billion annual economic impact on the State of New Jersey. For more information on NJIT, as well as its research and academic programs, please visit the university website at www.njit.edu.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise

Research Disclaimer Statement
NJIT is a public research university engaged in a variety of funded research, development and testing projects. NJIT’s research findings are not intended to create and may not be relied upon to create any rights enforceable at law by any party in any matter. Opinions or points of view expressed in any research report are presented for informational purposes only and do not constitute product approval or endorsement by NJIT. Neither NJIT nor any of its employees make any warranty, express or implied, or assume any legal liability or responsibility for the accuracy, completeness or any third party's use of such information, findings or data disclosed. Reference to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not constitute or imply NJIT’s endorsement, recommendation, or favoring by NJIT.